OBJECTIVE: Dunnigan-type familial partial lipodystrophy (FPLD) due to mutant LMNA is a monogenic form of insulin resistance. Affected subjects, especially women, are at increased risk of early coronary heart disease (CHD). Although common insulin resistance is associated with several biochemical perturbations, including elevated C-reactive protein (CRP), the biochemical profile in subjects with mutant LMNA is incompletely defined. METHODS AND RESULTS: We studied 35 nondiabetic adult FPLD subjects (of whom 24 were women) with either the LMNA R482Q or R482W missense mutations and 51 matched normal first-degree relatives (of whom 27 were women). Compared with normal controls, LMNA mutation carriers had significantly higher plasma insulin and more dyslipidemia, higher mean triglycerides and lower HDL cholesterol, significantly higher nonesterified free fatty acids and CRP, and significantly lower leptin and adiponectin than controls. Subgroup analyses showed that these differences were more pronounced in women. Other biomarkers such as resistin, fibrinogen, and plasminogen activator inhibitor-1 were not different between groups. CONCLUSIONS: LMNA mutations in nondiabetic patients with FPLD are associated with several metabolic and biochemical changes, particularly in women. The unfavorable profile might contribute to the increased susceptibility to CHD seen in LMNA mutation carriers.
OBJECTIVE: Dunnigan-type familial partial lipodystrophy (FPLD) due to mutant LMNA is a monogenic form of insulin resistance. Affected subjects, especially women, are at increased risk of early coronary heart disease (CHD). Although common insulin resistance is associated with several biochemical perturbations, including elevated C-reactive protein (CRP), the biochemical profile in subjects with mutant LMNA is incompletely defined. METHODS AND RESULTS: We studied 35 nondiabetic adult FPLD subjects (of whom 24 were women) with either the LMNAR482Q or R482W missense mutations and 51 matched normal first-degree relatives (of whom 27 were women). Compared with normal controls, LMNA mutation carriers had significantly higher plasma insulin and more dyslipidemia, higher mean triglycerides and lower HDL cholesterol, significantly higher nonesterified free fatty acids and CRP, and significantly lower leptin and adiponectin than controls. Subgroup analyses showed that these differences were more pronounced in women. Other biomarkers such as resistin, fibrinogen, and plasminogen activator inhibitor-1 were not different between groups. CONCLUSIONS:LMNA mutations in nondiabetic patients with FPLD are associated with several metabolic and biochemical changes, particularly in women. The unfavorable profile might contribute to the increased susceptibility to CHD seen in LMNA mutation carriers.
Authors: Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch Journal: J Lipid Res Date: 2011-11-07 Impact factor: 5.922
Authors: S P Y Wong; M Huda; P English; A Bargiota; J P H Wilding; A Johnson; R Corrall; J H Pinkney Journal: Diabetologia Date: 2005-11-17 Impact factor: 10.122
Authors: Daniel A de Luis; Pablo Bachiller; Teresa Palacios; Rosa Conde; Olatz Izaola; Beatriz de la Fuente; Jose M Eiros Bouza Journal: J Clin Lab Anal Date: 2012-09 Impact factor: 2.352
Authors: Lisa A Kosmiski; Peter Bacchetti; Donald P Kotler; Steven B Heymsfield; Cora E Lewis; Michael G Shlipak; Rebecca Scherzer; Carl Grunfeld Journal: J Clin Endocrinol Metab Date: 2007-10-16 Impact factor: 5.958
Authors: Adrian F Low; Christopher J O'Donnell; Sekar Kathiresan; Brendan Everett; Claudia U Chae; Stanley Y Shaw; Patrick T Ellinor; Calum A MacRae Journal: BMC Med Genet Date: 2005-10-31 Impact factor: 2.103